MARKET

TRVI

TRVI

Trevi Therapeutics
NASDAQ
14.13
-0.03
-0.21%
After Hours: 14.13 0 0.00% 16:41 05/22 EDT
OPEN
14.23
PREV CLOSE
14.16
HIGH
14.50
LOW
14.12
VOLUME
1.32M
TURNOVER
--
52 WEEK HIGH
16.12
52 WEEK LOW
5.38
MARKET CAP
2.01B
P/E (TTM)
-43.6920
1D
5D
1M
3M
1Y
5Y
1D
Trevi Therapeutics Price Target Maintained With a $23.00/Share by Needham
Dow Jones · 3d ago
Needham Reiterates Buy on Trevi Therapeutics, Maintains $23 Price Target
Benzinga · 3d ago
Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI) and AIM ImmunoTech (AIM)
TipRanks · 3d ago
Weekly Report: what happened at TRVI last week (0511-0515)?
Weekly Report · 5d ago
Weekly Report: what happened at TRVI last week (0504-0508)?
Weekly Report · 05/11 09:07
Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Joint (JYNT) and ImmunityBio (IBRX)
TipRanks · 05/08 13:10
TREVI THERAPEUTICS INC <TRVI.O>: STIFEL RAISES TARGET PRICE TO $30 FROM $18
Reuters · 05/08 11:22
U.S. RESEARCH ROUNDUP-Applied Materials, McDonald's, McKesson
Reuters · 05/08 07:12
More
About TRVI
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in patients with non-IPF interstitial lung disease, and refractory chronic cough. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed kappa-opioid receptor agonist and mu-opioid receptor antagonist. It has conducted a Phase II clinical trial and an open-label extension study of Haduvio in pruritus in patients with prurigo nodularis and a Phase IIb/III clinical trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program, and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.

Webull offers Trevi Therapeutics Inc stock information, including NASDAQ: TRVI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TRVI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TRVI stock methods without spending real money on the virtual paper trading platform.